Where Do Recent Small Molecule Clinical Development Candidates Come From?
Explore this paper's citation graph
Summary
The majority of clinical candidates were found to be structurally very different from their starting point and were more complex, and several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.
- Type
- article
- Published
- 2018-06-19
- Cited by
- 133
- References
- 143
- Access
- Open access
- OpenAlex
- https://openalex.org/W29920198
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:49312768
Keywords
Linguistics, Philosophy
References
- Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles
- Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.
- Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy.
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
- A bibliometric review of drug repurposing
- Principles of early drug discovery
- Discovery, design, and synthesis of indole-based EZH2 inhibitors.
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
- The influence of lead discovery strategies on the properties of drug candidates
- Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1).
- Natural Products as Sources of New Drugs over the 30 Years from 1981 to 2010
- SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
- Neoclassic Drug Discovery
- Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.
- Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.
- Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity
- Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.
- Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
- Impact of high-throughput screening in biomedical research
Cited by
- Solvents to Fragments to Drugs: MD Applications in Drug Design
- Advances in Lead Generation.
- An approach towards enhancement of a screening library: The Next Generation Library Initiative (NGLI) at Bayer - against all odds?
- Addressing Antimicrobial Resistance through New Medicinal and Synthetic Chemistry Strategies
- Fragment-to-Lead Medicinal Chemistry Publications in 2017.
- Second generation DNA-encoded dynamic combinatorial chemical libraries.
- Activity-based DNA-encoded library screening
- Highly diastereoselective synthesis of enantioenriched anti-α-allyl-β-fluoroamines.
- MCSS-based Docking and Improved Scoring of Protein-Nucleotide Complexes: I. A step forward to the Fragment-Based Design of Oligonucleotides
- Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases
- Plant natural fragments, an innovative approach for drug discovery
- Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.
- Deep Reinforcement Learning for Multiparameter Optimization in de novo Drug Design
- Opportunities and challenges in phenotypic screening for neurodegenerative disease research.
- Using Physicochemical Measurements to Influence Better Compound Design
- From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9.
- Promiscuity of in vitro secondary pharmacology assays and implications for lead optimization strategies.
- Docking finds GPCR ligands in dark chemical matter.
- FragPELE: Dynamic Ligand Growing within a Binding Site. A Novel Tool for Hit-To-Lead Drug Design
- DNA-Encoded Library Screening as a Core Platform Technology in Drug Discovery. Its Synthetic Method Development and Applications in DEL Synthesis.
Related papers
No related papers recorded.